Show simple item record

dc.contributor.authorHooton, Carmel
dc.contributor.authorKeohane, John
dc.contributor.authorClair, Jim
dc.contributor.authorAzam, Mohammad
dc.contributor.authorO'Mahony, Seamus
dc.contributor.authorCrosbie, Orla
dc.contributor.authorLucey, Brigid
dc.date.accessioned2012-02-03T15:05:16Z
dc.date.available2012-02-03T15:05:16Z
dc.date.issued2012-02-03T15:05:16Z
dc.identifier.citationEur J Gastroenterol Hepatol. 2006 Jun;18(6):595-9.en_GB
dc.identifier.issn0954-691X (Print)en_GB
dc.identifier.issn0954-691X (Linking)en_GB
dc.identifier.pmid16702847en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208846
dc.description.abstractBACKGROUND: The urea breath test (UBT) is the gold-standard non-invasive test for the detection of Helicobacter pylori infection, however, the lack of availability of the UBT due to the high cost of the test, and in particular the need for expensive analytical instrumentation, limits the usefulness of this method. Stool antigen assays may offer an alternative non-invasive method for the diagnosis of infection. OBJECTIVE: To compare the accuracy of three stool antigen assays (HpSA, IDEIA HpStAR, and ImmunoCard STAT) against the UBT for the primary diagnosis of H. pylori infection and for monitoring treatment outcome. METHODS: A total of 102 patients attending two gastroenterology day-case clinics for the investigation of dyspepsia were included. Each patient provided breath and stool samples for analysis. Patients who tested positive for H. pylori by the validated UBT were prescribed triple therapy and invited to return for repeat breath and stool sample analysis 6 weeks post-treatment. RESULTS: Of the 102 patients tested, 48 were diagnosed with H. pylori infection by the UBT. The HpSA assay interpreted 38 of these as positive (79% sensitive). Of the 54 UBT-negative patients the HpSA assay interpreted all 54 as negative (100% specific). The IDEIA HpStAR assay correctly identified 44 patients as positive (92% sensitive) and 50 as negative (92.5% specific). The ImmunoCard STAT assay interpreted 38 patients as positive (79% sensitive) and 52 as negative (96.3% specific). CONCLUSION: The findings indicate that the IDEIA HpStAR stool antigen kit is the most accurate assay of the three assays evaluated, and possibly represents a viable alternative to the UBT for the primary diagnosis of H. pylori infection and for monitoring treatment outcome.
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAntigens, Bacterial/*analysisen_GB
dc.subject.mesh*Breath Testsen_GB
dc.subject.meshCarbon Isotopes/diagnostic useen_GB
dc.subject.meshDyspepsia/etiologyen_GB
dc.subject.meshFeces/*microbiologyen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHelicobacter Infections/*diagnosisen_GB
dc.subject.meshHelicobacter pylori/*immunologyen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshSensitivity and Specificityen_GB
dc.subject.meshUrea/diagnostic useen_GB
dc.titleComparison of three stool antigen assays with the 13C- urea breath test for the primary diagnosis of Helicobacter pylori infection and monitoring treatment outcome.en_GB
dc.contributor.departmentCork University Hospital, Cork, Ireland. hootonc@shb.ieen_GB
dc.identifier.journalEuropean journal of gastroenterology & hepatologyen_GB
dc.description.provinceMunster
html.description.abstractBACKGROUND: The urea breath test (UBT) is the gold-standard non-invasive test for the detection of Helicobacter pylori infection, however, the lack of availability of the UBT due to the high cost of the test, and in particular the need for expensive analytical instrumentation, limits the usefulness of this method. Stool antigen assays may offer an alternative non-invasive method for the diagnosis of infection. OBJECTIVE: To compare the accuracy of three stool antigen assays (HpSA, IDEIA HpStAR, and ImmunoCard STAT) against the UBT for the primary diagnosis of H. pylori infection and for monitoring treatment outcome. METHODS: A total of 102 patients attending two gastroenterology day-case clinics for the investigation of dyspepsia were included. Each patient provided breath and stool samples for analysis. Patients who tested positive for H. pylori by the validated UBT were prescribed triple therapy and invited to return for repeat breath and stool sample analysis 6 weeks post-treatment. RESULTS: Of the 102 patients tested, 48 were diagnosed with H. pylori infection by the UBT. The HpSA assay interpreted 38 of these as positive (79% sensitive). Of the 54 UBT-negative patients the HpSA assay interpreted all 54 as negative (100% specific). The IDEIA HpStAR assay correctly identified 44 patients as positive (92% sensitive) and 50 as negative (92.5% specific). The ImmunoCard STAT assay interpreted 38 patients as positive (79% sensitive) and 52 as negative (96.3% specific). CONCLUSION: The findings indicate that the IDEIA HpStAR stool antigen kit is the most accurate assay of the three assays evaluated, and possibly represents a viable alternative to the UBT for the primary diagnosis of H. pylori infection and for monitoring treatment outcome.


This item appears in the following Collection(s)

Show simple item record